Pharmaceutical

Roche Pays $40M to Use Amunix Pharma's Half-Life Extension Tech

4 monthes ago   |   By Xconomy

Roche will pay Amunix Pharmaceuticals $40 million up front to use the company's proprietary technology to discover and develop new drugs outside of the oncology space. The clinically validated platform-XTEN-is a proprietary unstructured polypeptide, which when attached to molecules, can extend the half-life of drugs with low associated immunogenicity, according to Amunix. As per the agreement, Mountain View, CA-based Amunix could potentially receive up to $1.5 billion in development and sales milestones. Specific disease targets were not disclosed. Amunix CEO Angie You says the cash for IP...
Read more ...

 


Search by Tags

   Pharmaceutical      Pharma      Clinical      Pharmaceuticals      Drugs      Drug      National      National blog main      San Francisco      San Francisco blog main      Biotech      Deals      Life Sciences      Oncology      Roche  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations

Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations

Merck exited the holiday weekend with some fireworks of its own, announcing three major programs on Tuesday all related to investments in finding ways to treat and prevent... Read more ...

Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development

Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development

A stem cell biologist, a gene editing expert, and a data engineer walk into a room...and that's just a few of the people Daphne Koller has recruited in the past two years to... Read more ...

Site of LUX-ZEPLIN Dark Matter Search Project Carefully Ramps Up Science Work

Site of LUX-ZEPLIN Dark Matter Search Project Carefully Ramps Up Science Work

A photomultiplier tube array that is part of the LUX-ZEPLIN experiment at the Sanford Underground Research Facility in Lead, South Dakota. The photomultiplier tubes are... Read more ...

Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments

Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments

Privately held biotech ViaCyte has banked $27 million, the majority an installment of cash from a tranched $80 million Series D financing round it closed in late 2018. The... Read more ...

COVID-19 Sparks New Opportunities for Digital Health Companies

COVID-19 Sparks New Opportunities for Digital Health Companies

Clinicians and regulators are rethinking how healthcare is provided amid precautions prompted by COVID-19. In-person physician visits don't fit within the physical distancing... Read more ...

Bristol Myers Squibb Company: Associate Director of San Diego Global Capital...

Bristol Myers Squibb Company: Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused... Read more ...

Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of...

SAN DIEGO, May 26, 2020 - Sorrento Therapeutics, Inc. today announced it has received clearance from the U.S. Food and Drug Administration for its investigational new drug... Read more ...

Public Disclosure of COVID-19 Cases Is More Effective than Lockdowns

Read more ...

Gerald Joyce elected to Royal Swedish Academy of Sciences

LA JOLLA-Salk Professor Gerald Joyce, a pioneer in the field of in vitro evolution, has been elected to the prestigious Royal Swedish Academy of Sciences as a foreign member... Read more ...

Sugars that coat proteins are a possible drug target for pancreatitis

LA JOLLA-Pancreatitis is an inflammation of the pancreas that accounts for 275,000 hospitalizations in the United States annually. Patients who suffer from hereditary... Read more ...